Serum interleukin-21 level in patients with severe adverse cutaneous drug reactions and correlation with disease severity
Morsy, H., Ibrahim, F., Negm, D., Mwafey, I., Hanna, M. (2023). Serum interleukin-21 level in patients with severe adverse cutaneous drug reactions and correlation with disease severity. EKB Journal Management System, 8(1), 12-16. doi: 10.4103/jcmrp.jcmrp_133_21
Hanan A. Morsy; Fathiya A. Ibrahim; Dalia A. Negm; Ibrahim M. Mwafey; Mary A. Hanna. "Serum interleukin-21 level in patients with severe adverse cutaneous drug reactions and correlation with disease severity". EKB Journal Management System, 8, 1, 2023, 12-16. doi: 10.4103/jcmrp.jcmrp_133_21
Morsy, H., Ibrahim, F., Negm, D., Mwafey, I., Hanna, M. (2023). 'Serum interleukin-21 level in patients with severe adverse cutaneous drug reactions and correlation with disease severity', EKB Journal Management System, 8(1), pp. 12-16. doi: 10.4103/jcmrp.jcmrp_133_21
Morsy, H., Ibrahim, F., Negm, D., Mwafey, I., Hanna, M. Serum interleukin-21 level in patients with severe adverse cutaneous drug reactions and correlation with disease severity. EKB Journal Management System, 2023; 8(1): 12-16. doi: 10.4103/jcmrp.jcmrp_133_21